Moderna Inc. announced on Monday early-stage trials of the coronavirus vaccine produced positive results so far, adding it expects the final stage of the trials could begin in July. Commenting on the vaccine progress, Moderna’s Chief Medical Officer Tal Zaks revealed that “this interim phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 micrograms.” Moderna tested the vaccine on 45 males and non-pregnant females aged 18–55, who received two doses with the gap of 28 days between two injections. The company’s stocks surged 27.40% to sell for $83.84 per share in the premarket trade shortly before the start of today’s session.